California Public Employees Retirement System lifted its holdings in shares of Bio-Techne Corp (NASDAQ:TECH) by 2.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 70,000 shares of the biotechnology company’s stock after buying an additional 1,800 shares during the period. California Public Employees Retirement System owned about 0.19% of Bio-Techne Corp worth $8,225,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Bank of America Corp DE raised its holdings in shares of Bio-Techne Corp by 22.5% during the 1st quarter. Bank of America Corp DE now owns 249,413 shares of the biotechnology company’s stock worth $25,353,000 after buying an additional 45,852 shares in the last quarter. Eagle Asset Management Inc. raised its holdings in shares of Bio-Techne Corp by 5.0% during the 2nd quarter. Eagle Asset Management Inc. now owns 49,945 shares of the biotechnology company’s stock worth $5,868,000 after buying an additional 2,371 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Bio-Techne Corp by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 3,005,690 shares of the biotechnology company’s stock worth $305,528,000 after buying an additional 134,138 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Bio-Techne Corp by 174.8% during the 2nd quarter. American Century Companies Inc. now owns 731,589 shares of the biotechnology company’s stock worth $85,962,000 after buying an additional 465,398 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Bio-Techne Corp by 55.3% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 48,208 shares of the biotechnology company’s stock worth $5,664,000 after buying an additional 17,158 shares in the last quarter. 98.40% of the stock is owned by institutional investors.

Bio-Techne Corp (TECH) opened at 122.30 on Wednesday. The firm has a market cap of $4.57 billion, a PE ratio of 60.25 and a beta of 0.76. The firm has a 50-day moving average price of $121.47 and a 200-day moving average price of $113.95. Bio-Techne Corp has a one year low of $95.68 and a one year high of $124.00.

Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.10. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The company had revenue of $156.60 million during the quarter, compared to analyst estimates of $150.25 million. During the same quarter last year, the company earned $0.92 earnings per share. The firm’s quarterly revenue was up 16.2% on a year-over-year basis. On average, equities analysts expect that Bio-Techne Corp will post $3.99 EPS for the current fiscal year.

TECH has been the subject of a number of research analyst reports. Deutsche Bank AG set a $132.00 price target on Bio-Techne Corp and gave the stock a “buy” rating in a report on Wednesday, August 30th. Zacks Investment Research raised Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Thursday, July 6th. BidaskClub raised Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Wells Fargo & Company initiated coverage on Bio-Techne Corp in a report on Thursday, July 13th. They set a “market perform” rating for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Bio-Techne Corp currently has an average rating of “Buy” and a consensus target price of $127.50.

In other Bio-Techne Corp news, Director Karen A. Holbrook sold 1,059 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total transaction of $128,912.07. Following the sale, the director now owns 914 shares in the company, valued at $111,261.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 1,259 shares of company stock worth $152,436 in the last 90 days. Company insiders own 3.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bio-Techne Corp (TECH) Shares Bought by California Public Employees Retirement System” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/11/bio-techne-corp-tech-shares-bought-by-california-public-employees-retirement-system.html.

Bio-Techne Corp Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.